pipette
ENEnglish

RNA-targeted aminopyridine compounds provide a new antifungal strategy

J. Hwang, L. J. Sisto, T. Shi, M. C. Van Zandt, A. M. Pyle

PreprintUso en el mundo real

En palabras de los autores

While RNA is an emerging therapeutic target class, progress is limited by a shortage of well-defined targets in which ligand binding is coupled to measurable function. The group I intron, a self-splicing ribozyme essential in fungal mitochondria but absent from humans, offers both a tractable platform for exploring first principles of small molecule-RNA targeting and a selective antifungal target. We recalibrated an intron-splicing assay to approximate cellular conditions and performed an extensive, cryo-EM-guided structure-activity relationship campaign against the Candida albicans mtLSU intron. Ligands containing a flexible diamine outperformed conformationally constrained analogues, suggesting a general principle for engaging dynamic RNA surfaces and yielding lead aminopyridine 56 (IC 21.6 nM). Compound 56 synergizes with amphotericin B against C. albicans, suggesting a path for combination therapies. RT-qPCR confirmed direct target engagement in cells. This work establishes the fungal group I intron as a viable, mechanistically distinct antifungal target and a model platform for RNA-targeted discovery.

Resultado principalEl resumen no menciona limitaciones.

Apareció: sábado, 7 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.04.764270